OLUMIANT® Showed Significant Improvements in the Severity and Extent of Atopic Dermatitis and Other Patient-Reported Outcomes in Phase 3 Study Analyses

- Extended safety analysis across eight studies helps further define the known safety profile of OLUMIANT 2-mg in atopic dermatitis - INDIANAPOLIS ,  April 23, 2021  /PRNewswire/ -- Through new analyses of BREEZE-AD5 Phase 3 clinical trial data and an extended safety analysis across multiple